The Gene Therapy Program (GTP) at the University of Pennsylvania is a world-class research and development program based in Philadelphia. GTP features approximately 300 employees working in discovery research, translational science, vector production, and several additional core areas focused on the development of next-generation gene transfer vectors and their application toward the treatment of a variety of acquired and inherited diseases. Working with GTP, Passage Bio has optimized the traditional model, reducing the risks typically associated with the process.

With access to more vectors and better science, we are able to draw on the most promising scientific discoveries in the field of genetic medicine research and accelerate them to market.

Advantages Of Working With Gtp

• Active and engaged collaboration with the leaders in AAV-based gene therapy who have a deep expertise in therapeutic candidate development
• Ability to choose clinical indications validated through extensive testing in preclinical disease models
• Enhanced access to Penn’s Orphan Disease Center, which provides a resource in helping to identify patients with rare diseases as early as possible

Through GTP, we have options to numerous additional programs and can apply new research and technological innovations to our current and future programs where appropriate.